• Home
• » Patient Advice

Patient Advice

We will continue to care for our PIP patients under the terms and conditions confirmed in July 2012, details of which can be found below.

Following the publication of the final report by the PIP Expert Group on 18 June 2012, we have decided to amend our PIP aftercare in order to reach a wider range of patients. 

PIP patients with a medical need* inside 10 years of implantation will receive the following aftercare:

• Free surgeon consultation;
• Free implant removal;
• Removal and re-augmentation at a price of £2,500. There is no commercial gain at this price.
  

*A medical need is one of the following conditions, as identified by a scan and confirmed in a radiologist report:

• Rupture of implant;
• Evidence of silicone on the mediastinal lymph nodes;
  
• More than three axillary lymph nodes with silicon present;
• Any involved lymph node with a diameter greater than 2cm; and
• Evidence of implant shell collapse in excess of 30%.

What you should do

• If you experience symptoms such as pain, heat around the breast area, redness, inflammation or rippling, please call us on 0800 022 3387
  
• If you are unable to contact us on this number, please complete the PIP contact form

If you want to view the full report by the PIP Expert Group, please click here.

Report from the MHRA and the Department of Health - 31 July 2012

The MHRA and the Department of Health have today published supporting information used in the 2010 testing of PIP breast implants. This is additional to the testing results that were announced in September 2010.

To read the full report please click here

Release from the UK Parliament in conjunction with The Harley Medical Group July 2012

The Harley Medical Group has released its recommendations for the regulation of medical implants following the recent PIP crisis.

At the end of last year, it emerged that the implants contained industrial silicone instead of medical-grade fillers, which means they could be more likely to leak or rupture than other products.

The Harley Medical Group, which was one of the largest single users of the implants in Britain, trusted the safety of the products because they carried the CE mark – which it assumed meant they had been thoroughly tested.

However, it was discovered that testing was undertaken after the product had already been commercialised.

As a result, the Harley Medical Group has recommended that testing takes place before commercialisation. Furthermore, a compulsory breast implant register managed by the Medicines and Healthcare products Regulatory Agency (MHRA) should be introduced.

Under the recommendations, this would be complemented by an improved insurance system so that regulatory bodies would be able to take financial action in the event something similar should reoccur, enabling them to manage the situation appropriately. Similarly, authorities such as the MHRA should be made accountable.

According to the Harley Medical Group, these actions would help to ensure authorities are completely transparent to the public, ensuring breast surgery patients are fully aware of the situation.

Please click here to see the full recommendation by The Harley Medical Group and published by the British Parliament

What you should do

If you experience symptoms such as pain, heat around the breast area, redness, inflammation or rippling, please call us on 0800 022 3387.

If you are unable to contact us on this number, please complete the PIP contact form

As a UK healthcare organisation, all our clinics are registered with the Department of Health’s Care Quality Commission and we adhere strictly to the guidance of the Medicines and Healthcare products Regulatory Agency (MHRA) regarding breast implant information. The MHRA is an agency of the Department of Health and the only competent authority in the UK for medical devices such as breast implants. We have been, and continue to be, in close contact with them regarding the situation surrounding PIP breast implants, which the MHRA approved until they withdrew them from the UK market in March 2010.